AVEO Pharmaceuticals, Inc. (AVEO)
(Delayed Data from NSDQ)
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.94 USD
+0.04 (4.01%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.91 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
AVEO's Kidney Cancer Candidate Gets CHMP Recommendation
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its lead candidate, Fotivda (tivozanib), for the treatment of advanced renal cell carcinoma (RCC).
AVEO Reaches Enrollment Target in Pivotal Tivozanib Study
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) announced that the phase III study, TIVO-3, evaluating tivozanib in patients with refractory advanced renal cell carcinoma (RCC) has reached its enrollment target
Why Is AVEO Pharmaceuticals (AVEO) Up 25% Since the Last Earnings Report?
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) reported a first-quarter 2017 loss of 12 cents per share, narrower than the Zacks Consensus Estimate as well as year-ago loss of 13 cents.
AVEO Pharmaceuticals (AVEO) Down 17.4% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
AVEO Pharmaceuticals (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) reported a narrower-than-expected loss in the fourth-quarter 2016.
AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.
GW Pharmaceuticals (GWPH): What Awaits in Q4 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) is set to report fourth-quarter fiscal 2016 results on Dec 5. The company posted positive surprise of 57.80% in the last quarter.